Plans are also underway to begin three additional Phase Ib expansion studies focusing on different combinations and patient ...

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program ...

The phase 3 trial enrolled 1033 patients who had not received prior chemotherapy for mCRPC and had evidence of disease progression despite androgen deprivation therapy.

AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) compared ...

AstraZeneca has announced the discontinuation of the CAPItello-280 Phase III trial evaluating the efficacy and safety of ...

AstraZeneca to discontinue CAPItello-280 phase III trial of Truqap in metastatic castration-resistant prostate cancer: Cambridge, UK Wednesday, April 30, 2025, 10:00 Hrs [IST] Ast ...

Patients treated with darolutamide who reached ultra-low PSA at any time had lower risk of radiological progression or death versus those with PSA >=0.2 ng/mL, with a risk reduction of 91%, as did ...

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

Metastatic castration-resistant prostate cancer (mCRPC) is diagnosed by blood tests, imaging scans, and biopsies. Find out ...

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, focusing on Black patients with metastatic ...

Nauseef JT, Sun MP, Thomas C, et al. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer in patients with prior treatment with ...